MedPath

Pediatric Pectointercostal and ESP Block

Phase 4
Recruiting
Conditions
Postoperative Pain
Interventions
Drug: Pectointercostal and ESP block
Registration Number
NCT05590026
Lead Sponsor
Cukurova University
Brief Summary

American Society of Anaesthesiologist physical status II-III, aged between 2, 12 patients which underwent open cardiac surgery will recruited to this study. These subjects will Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the all patient under general anaesthesia. Totally bupivacaine %0.25 2.5 mg/kg will use blocks. 2 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine will apply intravenously at last 30 minutes of surgery postoperative analgesia to all patients. Postoperative pain and agitation assessment will perform with FLACC and Watcha scores

Detailed Description

American Society of Anaesthesiologist physical status II-III, aged between 2-12, 60 patients which underwent open cardiac surgery will recruited to this study. The patients were randomly allocated into two groups (1:1), via a computer-generated randomization list. Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the 30 patients under general anaesthesia in Group block and block will not perform to the control group. Sevoflurane+remifentanil and O2/air combination will perform to the all patients during the surgery. Totally bupivacaine %0.25 2.5 mg/kg will use for blocks.2 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine intravenously will apply for postoperative analgesia to the all patients at last 30 minutes of surgery. Postoperative pain and agitation assessment will perform with FLACC and Watcha scores. FLACC, Watcha scores, morphine consumption and complications will record.Paracetamol 10 mg/kg will repeat to the all patients at the 12th of postoperative period, intravenously. The patient controlled anesthesia with morphin will apply to the all patients. If the FLACC score is higher than 4, morphine 0.015 mg/kg will administer intravenously.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Ages between 2-12 years
  • ASA II-III children
  • The children who undergoing open heart surgery
Exclusion Criteria
  • Coagulopaty
  • Allergy of local anesthetic
  • Liver and renal failure
  • Obesity (BMI >35kg/m2)
  • Infection at the block area

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pectointercostal and ESP blockPectointercostal and ESP blockPectointercostal and ESP block will apply to the children after intubation. Totally bupivacain %0.25, 2.5 mg/kg will apply.
No BlockPectointercostal and ESP blockNo block will apply to the patient
Primary Outcome Measures
NameTimeMethod
Postoperative analgesia24 hours in Postanesthesia care unit (PACU)

Postoperative analgesia will asses Face, Legs, Activity, Cry, Consolability (FLACC) score in (Postanesthesia care unit) PACU till the 24th hours postoperatively. FLACC score reflects pain score between 0-10. 0 means zero pain, 10 means worse pain score

Postoperative morphine consumption24 hours in Postanesthesia care unit (PACU)

Postoperative morphine consumption will record till the postoperative 24 th hours

Secondary Outcome Measures
NameTimeMethod
Postoperative agitationFirst 24 hours at Postanesthesia care unit (PACU)

The patients will asses with Watcha score for postoperative agitation in Postanesthesia care unit (PACU) till the postoperative 24th hours. Watcha score reflects delirium score (scale between 0 to 4). A child with a score of \>2 on the Watcha score can be considered to have emergence delirium. (Points between 0-4) Watcah is one of the author's name.

Trial Locations

Locations (1)

Cukurova University

🇹🇷

Adana, Turkey

© Copyright 2025. All Rights Reserved by MedPath